Simplify Asset Management Inc. Grows Position in Leap Therapeutics, Inc. (NASDAQ:LPTX)

Simplify Asset Management Inc. raised its stake in Leap Therapeutics, Inc. (NASDAQ:LPTX) by 67.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,056,895 shares of the company’s stock after buying an additional 425,626 shares during the quarter. Simplify Asset Management Inc. owned about 4.13% of Leap Therapeutics worth $2,716,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of LPTX. Vanguard Group Inc. raised its holdings in shares of Leap Therapeutics by 111.7% in the 1st quarter. Vanguard Group Inc. now owns 867,708 shares of the company’s stock valued at $2,308,000 after buying an additional 457,904 shares during the period. Key Client Fiduciary Advisors LLC lifted its position in shares of Leap Therapeutics by 13.0% during the third quarter. Key Client Fiduciary Advisors LLC now owns 321,923 shares of the company’s stock worth $827,000 after purchasing an additional 37,067 shares in the last quarter. Acadian Asset Management LLC boosted its stake in shares of Leap Therapeutics by 349.3% in the first quarter. Acadian Asset Management LLC now owns 282,413 shares of the company’s stock valued at $750,000 after purchasing an additional 219,563 shares during the period. Finally, Marshall Wace LLP grew its holdings in shares of Leap Therapeutics by 268.2% in the second quarter. Marshall Wace LLP now owns 79,758 shares of the company’s stock valued at $156,000 after purchasing an additional 58,094 shares in the last quarter. Hedge funds and other institutional investors own 30.46% of the company’s stock.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $5.50 target price on shares of Leap Therapeutics in a report on Friday.

Leap Therapeutics Price Performance

Shares of LPTX stock traded down $0.14 during trading hours on Friday, reaching $2.75. 115,856 shares of the stock were exchanged, compared to its average volume of 237,856. The business’s fifty day moving average is $2.94 and its two-hundred day moving average is $2.58. The firm has a market capitalization of $70.40 million, a P/E ratio of -1.50 and a beta of 0.22. Leap Therapeutics, Inc. has a 12-month low of $1.34 and a 12-month high of $5.00.

Leap Therapeutics (NASDAQ:LPTX) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.10). As a group, equities research analysts predict that Leap Therapeutics, Inc. will post -1.84 earnings per share for the current fiscal year.

About Leap Therapeutics

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.